DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Eggermont AMM, Kicinski M, Blank CU. et al.
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol 01.04.2020;
6 (04) 519-527
DOI: 10.1001/jamaoncol.2019.5570.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.